FDA approves first drug directly targeting Alexander disease after three decades of research

The United States Food and Drug Administration has approved Zanvastro, the first therapeutic to directly target Alexander disease — a progressive and often fatal neurological disorder affecting fewer than one in a million people. The approval follows decades of research into the condition, which is caused by variants in the GFAP gene encoding glial fibrillary acidic protein, a structural component of astrocytes in the brain.

In clinical trials, Zanvastro demonstrated stabilisation of motor function in participants, with some patients showing measurable improvement in movement. The disease has until now had no approved disease-modifying treatments, leaving affected individuals and their families with limited options beyond supportive care.

Alexander disease typically presents in infancy or early childhood, though adult-onset forms exist. It is characterised by the accumulation of Rosenthal fibres — aggregates of GFAP — within astrocytes, leading to progressive neurological deterioration. The underlying genetic cause was identified in 2001, and subsequent research has aimed to reduce GFAP expression as a therapeutic strategy.

The source report, via ScienceDaily, does not name the developing institution or trial sponsor beyond the drug name Zanvastro. Genetic counsellors and clinicians working with families affected by rare leukodystrophies may wish to consult the FDA label and primary trial publications for further detail. Published guidance from relevant clinical bodies should be consulted regarding its application.